JP2023523016A5 - - Google Patents

Info

Publication number
JP2023523016A5
JP2023523016A5 JP2022564548A JP2022564548A JP2023523016A5 JP 2023523016 A5 JP2023523016 A5 JP 2023523016A5 JP 2022564548 A JP2022564548 A JP 2022564548A JP 2022564548 A JP2022564548 A JP 2022564548A JP 2023523016 A5 JP2023523016 A5 JP 2023523016A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
domain
composition according
chimeric
substance according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022564548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523016A (ja
JP7817948B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028775 external-priority patent/WO2021216956A1/en
Publication of JP2023523016A publication Critical patent/JP2023523016A/ja
Publication of JP2023523016A5 publication Critical patent/JP2023523016A5/ja
Application granted granted Critical
Publication of JP7817948B2 publication Critical patent/JP7817948B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022564548A 2020-04-23 2021-04-23 がんを処置するための組成物および方法 Active JP7817948B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014550P 2020-04-23 2020-04-23
US63/014,550 2020-04-23
PCT/US2021/028775 WO2021216956A1 (en) 2020-04-23 2021-04-23 Compositions and methods for treating cancer

Publications (3)

Publication Number Publication Date
JP2023523016A JP2023523016A (ja) 2023-06-01
JP2023523016A5 true JP2023523016A5 (enExample) 2024-04-26
JP7817948B2 JP7817948B2 (ja) 2026-02-19

Family

ID=78270118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564548A Active JP7817948B2 (ja) 2020-04-23 2021-04-23 がんを処置するための組成物および方法

Country Status (12)

Country Link
US (1) US20230140868A1 (enExample)
EP (1) EP4110822A4 (enExample)
JP (1) JP7817948B2 (enExample)
KR (1) KR20230019424A (enExample)
CN (1) CN115485301A (enExample)
AU (1) AU2021261003A1 (enExample)
BR (1) BR112022019939A2 (enExample)
CA (1) CA3172092A1 (enExample)
IL (1) IL296576A (enExample)
MX (1) MX2022013207A (enExample)
PH (1) PH12022553129A1 (enExample)
WO (1) WO2021216956A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020145669A1 (ko) 2019-01-10 2020-07-16 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물
KR102423686B1 (ko) * 2019-01-10 2022-07-21 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물
CN118284622A (zh) * 2021-09-30 2024-07-02 阿尔法贝塔控股有限责任公司 治疗癌症的组合物和方法
CN118542937A (zh) * 2023-02-24 2024-08-27 恒翼生物医药(上海)股份有限公司 抗αvβ3抗体和抗PD-1抗体的联合药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0968290B1 (en) * 1997-03-12 2004-12-15 SmithKline Beecham Corporation Anti-alphavbeta3 humanized monoclonal antibodies
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
KR100983997B1 (ko) * 2001-01-09 2010-09-28 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
HUE038848T2 (hu) * 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
BR122020002986A8 (pt) * 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
US10150800B2 (en) * 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
EP3113796A1 (en) * 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
WO2017053423A1 (en) * 2015-09-21 2017-03-30 Erasmus University Medical Center Anti-cd47 antibodies and methods of use
MX2019011717A (es) * 2017-03-31 2019-12-16 Univ California Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.
CN119367532A (zh) * 2019-08-02 2025-01-28 加利福尼亚大学董事会 用于靶向和杀死α-vβ-3（αvβ3）阳性癌症干细胞（CSC）以及治疗耐药性和转移性癌症的组合物和方法

Similar Documents

Publication Publication Date Title
JP2023523016A5 (enExample)
CN108976300B (zh) Pd-1结合分子和其使用方法
JP2024009818A5 (enExample)
AU2017331256B2 (en) CD123 binding proteins and related compositions and methods
US11667712B2 (en) Materials and methods for modulating t cell mediated immunity
JP2019500014A5 (enExample)
CN107614013A (zh) 结合lag‑3的分子和其使用方法
JP2023541816A5 (enExample)
AU2022369278A1 (en) ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF
JP2023517660A5 (enExample)
JP2021511298A5 (enExample)
JP2024524891A5 (enExample)
US20240336686A1 (en) Novel multi-specific molecules
KR20230079390A (ko) 감소된 응집 능력 및 감소된 소수성을 갖는 개선된 항-oxMlF 항체
JP2025508075A5 (enExample)
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
US20220153869A1 (en) Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof
WO2025245176A1 (en) Multispecific antibody constructs
EA052211B1 (ru) ВАРИАНТ Fc С ВЫСОКОЙ ТЕРМОСТАБИЛЬНОСТЬЮ И ОСЛАБЛЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
JP2024508764A5 (enExample)
NZ769634B2 (en) Anti-sirpa antibodies and methods of use thereof
NZ736674A (en) Anti-sortilin antibodies and methods of use thereof
NZ736674B2 (en) Anti-sortilin antibodies and methods of use thereof
NZ729157A (en) Anti-trem2 antibodies and methods of use thereof